Suppr超能文献

非霍奇金淋巴瘤的化疗(作者译)

[Chemotherapy in non-Hodgkin's lymphomas (author's transl)].

作者信息

Schmidt C G

出版信息

Strahlentherapie. 1977 May;153(5):283-92.

PMID:69343
Abstract

The type of therapy in non-Hodgkin's lymphomas (NHL) depends on the state of the disease and on histological classification. As in Hodgkin's lymphoma radiotherapy is indicated with localized disease, whereas chemotherapy is given in disseminated cases. In contrast to Hodgkin's lymphoma chemotherapy is indicated earlier (already in most stage II cases), since dissemination may occur outside the typical lymph node areas. Division of NHLs according to higher or lower degree of malignancy is possible histologically on the basis of the Kiel classification as well as of the Rappaport classification. Low-grade malignant lymphomas are treated best with conventional doses of an alkylating agent. An intensive combined chemotherapy is not indicated. Because of the tendency to early and frequent relapses a cyclic maintenance therapy with an alkylating agent is incidated. High-grade malignant lymphomas have to be treated with agressive combination chemotherapy in order to get the patient into complete remission with the possibility for a long relapse-free interval. Up to now there is no indication that any of the published chemotherapy combinations is definitely superior to the others. It is most important to apply the therapy consequently for at least six months. The value of a maintenance therapy is not yet proven.

摘要

非霍奇金淋巴瘤(NHL)的治疗类型取决于疾病状态和组织学分类。与霍奇金淋巴瘤一样,局限性疾病采用放射治疗,而播散性病例则进行化疗。与霍奇金淋巴瘤不同,化疗更早开始应用(大多数II期病例就已开始),因为播散可能发生在典型淋巴结区域之外。根据基尔分类法以及拉帕波特分类法,从组织学角度可以将NHL分为高恶性度或低恶性度。低恶性度淋巴瘤最好用常规剂量的烷化剂治疗。不建议进行强化联合化疗。由于早期和频繁复发的倾向,需要用烷化剂进行周期性维持治疗。高恶性度淋巴瘤必须采用积极的联合化疗,以使患者完全缓解,并有可能获得较长的无复发间期。到目前为止,没有迹象表明已公布的任何化疗方案绝对优于其他方案。至关重要的是,至少连续应用该疗法六个月。维持治疗的价值尚未得到证实。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验